Chapter 14. Membranous Nephropathy

  1. Donald A. Molony MD3,4 and
  2. Jonathan C. Craig MD, PhD5,6
  1. Fernando C. Fervenza MD, PhD1 and
  2. Daniel C. Cattran MD, FRCP2

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch14

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Fervenza, F. C. and Cattran, D. C. (2008) Membranous Nephropathy, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch14

Editor Information

  1. 3

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 4

    Houston Medical School, Houston, Texas, USA

  3. 5

    School of Public Health, University of Sydney, Australia

  4. 6

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. 1

    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

  2. 2

    Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • idiopathic membranous nephropathy (MN);
  • agents modifying natural course of disease - angiotensin converting enzyme inhibitors (ACEi);
  • immunosuppressive therapy;
  • conservative therapy and controlling edema, dietary protein intake, blood pressure, and hyperlipidemia;
  • MN treatment algorithm;
  • adrenocorticotropic hormone (ACTH);
  • control of NS with CR or PR - associated with prolonged renal survival and slower renal disease progression


This chapter contains sections titled:

  • Introduction

  • Natural history

  • Clinical manifestations

  • Predicting factors

  • Response measurements

  • Treatment

  • References